NASDAQ:PRLD

Prelude Therapeutics Q1 2025 Earnings Results & Report

Prelude Therapeutics logo
$3.32 -0.09 (-2.64%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$3.32 0.00 (-0.15%)
As of 11/17/2026 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Prelude Therapeutics beat analyst earnings expectations in its Q1 2025 results, released May 6, 2025. The company reported EPS of -$0.42 versus the -$0.47 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Prelude Therapeutics EPS Results

Actual EPS
-$0.42
Consensus EPS
-$0.47
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Prelude Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prelude Therapeutics Q1 2025 Earnings FAQ

Prelude Therapeutics (NASDAQ:PRLD) reported earnings of -$0.42 per share for Q1 2025, beating the consensus estimate of -$0.47. The report was announced on Tuesday, May 6, 2025.

Prelude Therapeutics Earnings Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
Prelude Therapeutics (PRLD) Expected to Release Earnings on Wednesday
See More Prelude Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prelude Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prelude Therapeutics and other key companies, straight to your email.

About Prelude Therapeutics

Prelude Therapeutics (NASDAQ:PRLD) is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival.

Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude’s pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.

Founded in 2016 and based in Wilmington, Delaware, Prelude conducts its drug discovery and development work in the United States. Its programs are intended to address unmet needs in oncology through targeted approaches.

View Prelude Therapeutics Profile